Date: 2018-01-02
Type of information: Licensing agreement
Compound: Aplidin® (plitidepsin)
Company: PharmaMar (Spain) Megapharm (Israel)
Therapeutic area: Cancer - Oncology
Type agreement: licensing - commercialisation - distribution
Action mechanism:
- depsipeptide derivative. Plitidepsin is an investigational anticancer agent of marine origin, originally obtained from the tunicate Aplidium albicans. It specifically binds to the eEF1A2 and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis (programmed death).
- Plitidepsin is currently in clinical development for hematological cancers, including a Phase III study in relapsed or refractory multiple myeloma, a Phase Ib trial in relapsed or refractory multiple myeloma as a triple combination of plitidepsin, bortezomib and dexamethasone, and a Phase II study in relapsed or refractory angioimmunoblastic T-cell lymphoma. A Phase III trial in relapsed or refractory multiple myeloma has been completed. Plitidepsin has received orphan drug designation by the EMA and the FDA.
Disease: multiple myeloma
Details:
- • On January 2, 2018, PharmaMar has announced a commercialization and distribution license agreement with Megapharm for the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian Authority. According to the agreement Megapharm will register Aplidin® on behalf of PharmaMar and distribute the compound in both regions. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use.
Financial terms:
Latest news:
Is general: Yes
